Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 0615-8313

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 0615-8313). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Donepezil HCl 10mg Tab 8313 Macleods 1)

FDA Label Image

Fig-9 (Donepezil HCl 10mg Tab 8313 Macleods 10)

The text seems to be a graph displaying the change from baseline in ADCS-ADL score with Donepezil Hydrochloride 10 mg/day and placebo, over 3 and 6 months of drug treatment. It is showing the mean values and standard error (SE) for both treatment groups. The graph indicates that there was clinical improvement in the ADCS-ADL score in the Donepezil Hydrochloride group compared to placebo.*

FDA Label Image

Fig-10 (Donepezil HCl 10mg Tab 8313 Macleods 11)

This appears to be a graph showing the Cumulative Percentage of Patients for Donepezil Hydrochloride 10mg/day and Placebo, with the x-axis showing the ADCS-ADL Change from Baseline and the y-axis showing the percentage of patients. Not enough information is provided to interpret the graph beyond this.*

FDA Label Image

Fig-11 (Donepezil HCl 10mg Tab 8313 Macleods 12)

This text presents a chart showing the effects of Donepezil Hydrochloride at different dosages on the clinical improvement and decline of patients over a 24-week period. The chart compares the effects of treatment with 23 mg/day and 10 mg/day dosages of the drug, and measures the clinical improvement or decline of the patients over the course of the drug treatment. No other details or context is available.*

FDA Label Image

Fig-12 (Donepezil HCl 10mg Tab 8313 Macleods 13)

FDA Label Image

Fig-13 (Donepezil HCl 10mg Tab 8313 Macleods 14)

This appears to be a chart showing the percentage of patients who underwent treatment with two different doses of Donepezil Hydrochloride (either 10 mg/day or 23 mg/day) and their corresponding improvements according to the CIBIC-plus rating scale. The scale ranges from "Markedly Improved" to "Markedly Worse".*

FDA Label Image

Donepezil 10mg Tab Bingo Card Label (Donepezil HCl 10mg Tab 8313 Macleods 15)

FDA Label Image

Fig-1 (Donepezil HCl 10mg Tab 8313 Macleods 2)

This appears to be a chart or graph showing the ADAS-cog Change from Baseline in patients receiving different dosages of Donepezil Hydrochloride and Placebo over a period of 30 weeks of drug treatment. The x-axis shows the duration in weeks and the y-axis shows the scores ranging from -2 to 2. There are three lines representing Clinical Improvement, Placebo, and the two different dosages of Donepezil Hydrochloride (10mg/day and 5mg/day). The baseline is marked at 0, and the graph shows the change in ADAS-cog scores over time.*

FDA Label Image

Fig-2 (Donepezil HCl 10mg Tab 8313 Macleods 3)

This is a description of a study comparing the effects of Donepezil Hydrochloride (10mg and 5mg) with Placebo on the cognitive function of patients, as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). The table shows the cumulative percentage of patients in treatment and placebo groups who experienced no change, as well as improvements (4/7 points) or worsening (7 points) of condition over a certain period of time. The results suggest that Donepezil Hydrochloride (both doses) is more effective than the Placebo in improving cognitive function.*

FDA Label Image

Fig-3 (Donepezil HCl 10mg Tab 8313 Macleods 4)

This appears to be a data table showing the percentages of patients who received a certain dosage of Donepezil Hydrochloride and the resulting improvement or worsening of their condition according to the CIBIC-plus Rating. The table also includes a placebo group.*

FDA Label Image

Fig-4 (Donepezil HCl 10mg Tab 8313 Macleods 5)

FDA Label Image

Fig-5 (Donepezil HCl 10mg Tab 8313 Macleods 6)

This is a table showing the change in ADAS-cog (a score that measures cognitive function in Alzheimer's disease) for patients taking different doses of Donepezil Hydrochloride and placebo, along with the cumulative percentage of patients who experienced a certain level of improvement or decline in cognitive function. The table suggests that higher doses of Donepezil Hydrochloride (5 mg/day and 10 mg/day) led to greater improvement in cognitive function compared to placebo and lower doses of the medication.*

FDA Label Image

Fig-6 (Donepezil HCl 10mg Tab 8313 Macleods 7)

FDA Label Image

Fig-7 (Donepezil HCl 10mg Tab 8313 Macleods 8)

FDA Label Image

Fig-8 (Donepezil HCl 10mg Tab 8313 Macleods 9)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.